Novo Nordisk and Eli Lilly are offering discounts to encourage more insurance coverage of the medicines, which carry price tags of over $1,000 a month.

Weight-loss drugs like Ozempic are booming in popularity, but experts warn they aren't silver bullets for obesity.

Weight loss drugs have gained attention as a tool to help combat obesity, but understanding how they work, who they’re for, and their potential downsides is key to making informed decisions.

F ROM LOS ANGELES to London, weight-loss drugs such as Ozempic are reshaping culture as much as waistlines. Some Ozempic-takers have tiny appetites and dine at unusual hours to avoid spells of nausea.

Many people are doing an end-run around their doctor's office, reaching out to potentially unreliable sources that promise to set them up with Wegovy, Zepbound and other weight-loss drugs.

One of the researchers described the circumstances that led to the discovery as “serendipity.” This year’s prestigious Lasker medical awards recognize a trio of scientists without whom Ozempic and other blockbuster weight-loss drugs might not exist.